Cullinan Therapeutics, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2019 | — | $97.0M | — |
| Mar 2020 | — | $106.8M | — |
| Jun 2020 | — | $97.7M | — |
| Sep 2020 | — | $87.6M | — |
| Dec 2020 | — | $199.0M | $168.2M |
| Mar 2021 | — | $466.9M | $293.5M |
| Jun 2021 | — | $455.5M | $123.7M |
| Sep 2021 | — | $443.4M | $88.1M |
| Dec 2021 | — | $425.0M | $59.8M |
| Mar 2022 | — | $418.7M | $76.1M |
| Jun 2022 | — | $604.5M | $353.6M |
| Sep 2022 | — | $586.1M | $242.7M |
| Dec 2022 | — | $535.0M | $156.2M |
| Mar 2023 | — | $485.6M | $122.1M |
| Jun 2023 | — | $499.6M | $141.8M |
| Sep 2023 | — | $468.8M | $64.8M |
| Dec 2023 | — | $453.7M | $98.4M |
| Mar 2024 | — | $425.7M | $74.2M |
| Jun 2024 | — | $656.2M | $115.0M |
| Sep 2024 | — | $627.9M | $102.1M |
| Dec 2024 | — | $590.3M | $83.0M |
| Mar 2025 | — | $551.8M | $76.7M |
| Jun 2025 | — | $492.1M | $72.8M |
| Sep 2025 | — | $451.4M | $103.3M |
| Dec 2025 | — | $408.7M | $88.3M |
| Mar 2026 | — | $366.2M | $75.1M |
| Jun 2026 | — | $321.8M | $78.6M |